MILAN, Italy--(BUSINESS WIRE)--Sorin Group (MIL:SRN), the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announced today the first patient enrolment in the e-OPTIMA registry. The e-OPTIMA registry is designed to assess the clinical performance of the Sorin Group OPTIMA Drug-Eluting Stent (DES) Carbostent in the treatment of real-world patients in routine clinical practice. The OPTIMA DES features a specially designed delivery system that allows for optimal DES expansion at implant. The registry will involve 1,000 patients throughout the world (except in the U.S. and Japan).
